Accueil > Actualité
Actualite financiere : Actualite bourse

GSK: decisions in the Zantac (ranitidine) litigation

(CercleFinance.com) - GSK has confirmed that it has taken the first step to appeal the Delaware Superior Court's recent Daubert decision, which enables plaintiffs to testify as experts in the Zantac (ranitidine) litigation in Delaware.


"GSK strongly disagrees with the Delaware Superior Court's ruling and has filed an application with the court to appeal to the Delaware Supreme Court for interlocutory review of the decision. Pfizer, Sanofi, and Boehringer Ingelheim are all parties to the application", the group says.

GSK also welcomes the plaintiff's voluntary dismissal of the forthcoming Zantac (Kasza) case, which was due to go to trial in an Illinois state court on 10 June 2024.

Following 16 epidemiological studies of human data on the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of cancer, GSK says.

"GSK strongly disagrees with the Delaware Superior Court's ruling and has filed an application with the court to appeal to the Delaware Supreme Court for interlocutory review of the decision. Pfizer, Sanofi, and Boehringer Ingelheim are all parties to the application", management adds.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
 

societes

marches

tendances

 
Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.